ABSTRACT
In the present study we aimed to establish the seroprevalence of T. gondii and N. caninum in stray and domiciled cats from the municipality of Patos, Paraíba state, Brazil. Blood samples were collected from 201 animals: 132 domiciled cats and 69 stray cats. An epidemiological questionnaire was conducted with all cat owners. Indirect immunofluorescent antibody test (IFAT) was performed at cut-offs of 1:16 and 1:50 for T. gondii and N. caninum, respectively. Overall prevalence of seroreagent cats for T. gondii was 43.8 percent. We found a prevalence of 47.7percent in domiciled cats and 36.2 percent in stray cats. Antibody titers ranged from 1:16 (cut-off) to 1:8192; 1:128 was the most frequent titer. No statistical difference was observed between domiciled cats and stray cats. Correlation was verified between seroreagent for T. gondii and age and hunting habit (P<0.05). No animals tested seroreagent for N. caninum. It was possible to conclude that there is high prevalence of cat seroreagent for T. gondii and that N. caninum is not present in cats from the area studied...
Este trabalho teve como objetivo determinar frequência de Toxoplasma gondii e Neospora caninum em gatos domiciliados e errantes do município de Patos, mesorregião do sertão paraibano. Foram coletadas amostras de sangue provenientes de 201 gatos, 132 domiciliados e 69 errantes. Nos domiciliados, foi aplicado um questionário epidemiológico aos proprietários. A reação de imunofluorescência indireta (RIFI) foi realizada levando-se em consideração os pontos de corte 1:16 e 1:50 para T. gondii e N. caninum, respectivamente. Foi obtida uma prevalência total de 43.8 por cento de gatos sororreagentes para T. gondii. Nos domiciliados, a prevalência foi de 47,7 por cento (63/132), e nos errantes de 36,2 por cento (25/69), com títulos variando de 1:16 a 1:8192, sendo a titulação 1:128 a mais frequente. Não se observou diferença estatística entre animais domiciliados e errantes. Verificou-se correlação entre sororreagentes a T. gondii e idade e hábito de caçar (P<0.05). Nenhum animal foi sororreagente para N. caninum. Concluiu-se que é alta a prevalência de gatos sororreagentes para T. gondii e que o N. caninum não está presente em gatos na área estudada...
Subject(s)
Animals , Cats , Cats/parasitology , Neospora/isolation & purification , Blood/parasitology , Fluorescent Antibody Technique, Indirect/veterinary , Toxoplasma/isolation & purification , Animal Distribution , Animals, Domestic , Animals, Wild/parasitology , Parasitic Diseases, AnimalABSTRACT
We have treated 10 patients suffering from kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) at a dose of 2 mg/kg/d for 5 d, following an earlier study in which this dosage for 7 d was found to cure all of 9 patients, with no relapse during 12 months. In the present study, all patients demonstrated initial resolution of disease. Parasites were absent upon bone marrow re-aspiration 2 weeks after therapy; no spleen extended beyond the costal margin 2 months after therapy; white blood cell counts, platelet counts, and serum levels of albumin rapidly returned to normal. Although one patient relapsed at 5 months, 8 of the other 9 patients had spleens of normal size (undetectable on deep palpation) at 12 months after therapy. Fever, sometimes accompanied by increased respiratory rate, occurred on the first day of drug infusion in 8 of 10 patients and was more severe in patients < 6 years old. Pre-medication with a non-steroidal anti-inflammatory agent (diclofenac potassium) before the next 4 infusions protected against this side effect in 5 of 6 patients. The results of this and our previous study suggest that the most appropriate regimen of Amphocil for kala-azar is 2 mg/kg/d for 7 d, with pre-medication each day, in patients aged > 5 years.
Subject(s)
Amphotericin B/analogs & derivatives , Antiprotozoal Agents/therapeutic use , Cholesterol Esters/therapeutic use , Leishmaniasis, Visceral/drug therapy , Adolescent , Adult , Amphotericin B/adverse effects , Amphotericin B/therapeutic use , Antiprotozoal Agents/adverse effects , Brazil , Child , Child, Preschool , Cholesterol Esters/adverse effects , Diclofenac/therapeutic use , Female , Fever/prevention & control , Humans , Infant , MaleABSTRACT
Amphotericin B is an effective but toxic antileishmanial agent. Lipid-encapsulated amphotericin B should have a high therapeutic index for visceral leishmaniasis because reticuloendothelial cells, the sole site in which Leishmania is found, will phagocytize and concentrate the complex. Amphotericin B cholesterol dispersion (Amphocil; 2 mg/[kg.d] intravenously) was administered to 10 Brazilians with kala-azar for 10 days (cohort 1) and to 10 Brazilians with kala-azar for 7 days (cohort 2). All patients were successfully treated: 19 of the 20 patients were without visible parasites in the bone marrow; the mean time to afebrility was 4.2 days; spleen size regressed by a mean of 79% 2 months after therapy; and no patient had clinical or laboratory abnormalities by the end of 6-12 months of follow-up. Side effects were fever and chills accompanied by respiratory distress, but not nephrotoxicity, in children < 3 years of age.
